Investigational drug · Phase 3
TJ0113
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sarcopenia, Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "TJ0113"
First trial start
2025
Jul 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TJ0113", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcopenia
- Parkinson's Disease (PD)
- Parkinson Disease 6, Early-Onset
- Depression
Approved drugs for the same conditions: Parkinson's disease · Depression (major depressive disorder) · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "TJ0113" as an intervention, largest first.
- Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's DiseasePivotal-lookingRecruiting
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07741045 · 300 participants (planned) · Start Nov 5, 2026 · Primary completion Jan 15, 2028
Drug: TJ0113 200mg; TJ0113 400mg and 1 more · For: Parkinson's Disease (PD); Parkinson Disease 6, Early-Onset
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 21 sites in all
- Clinical Study of TJ0113 Capsule in the Treatment of Patients With SarcopeniaPivotal-lookingRecruiting
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07620938 · 204 participants (planned) · Start Jun 12, 2026 · Primary completion Aug 22, 2027
Drug: TJ0113; TJ0113 and 2 more · For: Sarcopenia
Sites: Hangzhou, China
- Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's DiseasePivotal-lookingCompleted
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06596005 · 149 participants · Start Sep 18, 2024 · Primary completion Sep 3, 2025
Drug: TJ0113 200mg; TJ0113 400mg and 1 more · For: Parkinson Disease
Sites: Hangzhou, China
- Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderPivotal-lookingCompleted
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07018245 · 149 participants · Start Jul 9, 2025 · Primary completion Jun 25, 2026
Drug: TJ0113; Placebo · For: Depression
Sites: Hangzhou, China
- Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy SubjectsPivotal-lookingCompleted
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07394452 · 130 participants · Start Aug 4, 2023 · Primary completion Feb 5, 2024
Drug: TJ0113 Capsules · For: Healthy Subjects
Sites: Hangzhou, China
- A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing LossNot yet recruiting
Yilai ShuAcademic, hospital or other
NCT07012746 · 60 participants (planned) · Start Jun 7, 2025 · Primary completion Dec 2026
Drug: TJ0113 capsules; Placebo capsules · For: Age Related Hearing Loss; Deafness
Sites: Shanghai, China
Hangzhou PhecdaMed Co., Ltd.Industry
NCT06832540 · 6 participants · Start Feb 19, 2025 · Primary completion Mar 5, 2025
Drug: [14C]TJ0113 · For: Healthy Chinese Subjects
Sites: Wuxi, China
Newest research
PubMed records naming it or its code names, newest first.
- Novel mitophagy activator TJ0113 restricts cytosolic mtDNA to suppress ZBP1-driven inflammation in acute lung injury.
Chen X, Xing S, Cen X, et al. · Redox Biol 2026
- Preclinical safety and toxicokinetic evaluation of TJ0113, a first-in-class mitophagy inducer for Parkinson's disease.
Tian Y, Wang F, Shen J, et al. · Toxicol Appl Pharmacol 2025
- Mitophagy Reprograms Lactate Metabolism to Suppress THBS1 via H3K18la Reduction, Alleviating Intervertebral Disc Degeneration.
Wang K, Wu X, Li H, et al. · Research (Wash D C) 2025
- Correction: Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury.
Liu Z, Fang D, Chen K, et al. · Front Pharmacol 2025
- Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury.
Liu Z, Fang D, Chen K, et al. · Front Pharmacol 2025
- TJ0113-induced mitophagy in acute liver failure detected by Raman microspectroscopy.
Huang C, Liao J, Cen X, et al. · Redox Biol 2025
Also in development for Sarcopenia
- EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cellsWJ-MSCs, EN001Phase 22 trials
ENCell · Sarcopenia, Charcot-Marie-Tooth Disease Type 1A
- AMC6156Phase 21 trial
Animuscure Inc. · Sarcopenia in Elderly, Sarcopenia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.